Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA

BofA raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $145 from $140 and keeps a Buy rating on the shares after the company preannounced Q4 Imcivree revenues of roughly $57M, which was slightly ahead of Street estimates. While the firm notes the press release did not provide color on the growth in number of patients on reimbursed therapy, it expects growth dynamics continue to be stable for the existing Imcivree franchise, the analyst tells investors.